化工儀器網(wǎng)
資料下載
測(cè)量應(yīng)用案例-20210105
閱讀：115 發(fā)布時(shí)間：2021-1-20| 提 供 商 | 美國(guó)布魯克海文儀器公司 | 資料大小 | 11.1MB |
|---|---|---|---|
| 資料圖片 | 下載次數(shù) | 24次 | |
| 資料類型 | PDF 文件 | 瀏覽次數(shù) | 115次 |
| 免費(fèi)下載 | 點(diǎn)擊下載 |
作者：Jiani Xieab; Chengyan Wangbc; Ning Wange; Shuang Zhub; Linqiang Meibc; Xiao Zhangb; Yuan Yongg; Lele Lid; Chunying Chend; Changshui Huange; Zhanjun Gubc; Yuliang Lif; Yuliang Zhaocd
aCollege of Pharmacy and Biological Engineering, Chengdu University, Chengdu, 610106, China
bCAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing, 100049, China
cCenter of Materials Science and Optoelectronics Engineering, College of Materials Science and Optoelectronic Technology, University of Chinese Academy of Sciences, Beijing, 100049, China
dCAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology of China, Chinese Academy of Sciences, Beijing, 100190, China
eQingdao Institute of Bioenergy and Bioprocess Technology, Chinese Academy of Sciences, Qingdao, 266101, China
fInstitute of Chemistry, Chinese Academy of Sciences, Beijing, 100190, China
gCollege of Chemistry and Environment Protection Engineering, Southwest Minzu University, Chengdu, 610041, China
摘要：X-ray irradiation-induced toxicity to gastrointestinal tract become a significant clinical problem when using radiotherapy for treating abdominal tumors neighbored to gastrointestinal tissue, which not only often prevents these tumors from receiving a definitive therapeutic dose but also causes a series of gastrointestinal diseases, such as anorexia, abdominal pain, diarrhea and hematochezia. And thus it seriously reduces the therapeutic outcome and life quality of patients. Therefore, the development of gastrointestinal radioprotectors is essential. However, the commercial gastrointestinal radioprotectors in clinical are still rare. In view of this, we prepared bovine serum albumin (BSA) modified graphdiyne (GDY) nanoparticles (GDY-BSA NPs) and for the first time studied its gastrointestinal radioprotection ability. The unique advantages of GDY nanomaterial, including high free radical scavenging ability, good chemical stability in gastric acid condition, relatively longer residence time in gastrointestinal tract and good biosafety under oral administration, provide the favorable prerequisites for it to be used as the gastrointestinal radioprotector. In vitro experimental results indicated that the GDY-BSA NPs powerfully reduced DNA damage and improved viability of the irradiated gastrointestinal cells. In vivo results showed that the GDY-BSA NPs significantly decrease radiation-induced diarrhea, weight loss, and gastrointestinal tissue pathological damage of mice. Furthermore, we also deeply studied the gastrointestinal radioprotective mechanism of GDY-BSA NPs, which indicated that the GDY-BSA NPs effectively inhibited reactive oxygen species (ROS)-induced apoptosis signal pathway, and thus reduced gastrointestinal cell apoptosis. Our work for the first time employed BSA-GDY NPs to mitigating radiation-induced gastrointestinal tract damage, which not only promotes the exploration of new gastrointestinal tract radioprotectors, but also is the good guidance for the treatment of gastrointestinal diseases by nano-drug.